WO2015058664A8 - 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途 - Google Patents

淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途 Download PDF

Info

Publication number
WO2015058664A8
WO2015058664A8 PCT/CN2014/088944 CN2014088944W WO2015058664A8 WO 2015058664 A8 WO2015058664 A8 WO 2015058664A8 CN 2014088944 W CN2014088944 W CN 2014088944W WO 2015058664 A8 WO2015058664 A8 WO 2015058664A8
Authority
WO
WIPO (PCT)
Prior art keywords
icaritin
preventing
preparing medicament
hematocytopenia
treating
Prior art date
Application number
PCT/CN2014/088944
Other languages
English (en)
French (fr)
Other versions
WO2015058664A1 (zh
Inventor
赵志全
姚景春
李欣
关永霞
李光艳
Original Assignee
鲁南制药集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201310493718.4A external-priority patent/CN104546823B/zh
Priority claimed from CN201310646101.1A external-priority patent/CN104688722B/zh
Application filed by 鲁南制药集团股份有限公司 filed Critical 鲁南制药集团股份有限公司
Priority to EP14855388.6A priority Critical patent/EP3061452B1/en
Priority to KR1020167013370A priority patent/KR101891505B1/ko
Priority to US15/030,671 priority patent/US10555962B2/en
Priority to ES14855388T priority patent/ES2698620T3/es
Priority to JP2016525940A priority patent/JP6294476B2/ja
Publication of WO2015058664A1 publication Critical patent/WO2015058664A1/zh
Publication of WO2015058664A8 publication Critical patent/WO2015058664A8/zh
Priority to US16/724,573 priority patent/US10799521B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本申请涉及淫羊藿苷元在制备预防或治疗血细胞减少的药物中的用途。特别地，淫羊藿苷元可用于预防或治疗化疗药物导致的骨髓抑制，也可用于预防或治疗血小板减少症，例如免疫性血小板减少症。
PCT/CN2014/088944 2013-10-21 2014-10-20 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途 WO2015058664A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP14855388.6A EP3061452B1 (en) 2013-10-21 2014-10-20 Icaritin for use in preventing or treating hematocytopenia
KR1020167013370A KR101891505B1 (ko) 2013-10-21 2014-10-20 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 안히드로이카리틴의 용도
US15/030,671 US10555962B2 (en) 2013-10-21 2014-10-20 Use of icaritin in preparing medicament for preventing or treating hematocytopenia
ES14855388T ES2698620T3 (es) 2013-10-21 2014-10-20 Icaritina para uso en la prevención o el tratamiento de la hematocitopenia
JP2016525940A JP6294476B2 (ja) 2013-10-21 2014-10-20 血球減少を予防又は治療するための薬物の製造におけるアンヒドロイカリチンの使用
US16/724,573 US10799521B2 (en) 2013-10-21 2019-12-23 Use of icaritin in preparing medicament for preventing or treating hematocytopenia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201310493718.4 2013-10-21
CN201310493718.4A CN104546823B (zh) 2013-10-21 2013-10-21 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途
CN201310646101.1A CN104688722B (zh) 2013-12-04 2013-12-04 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途
CN201310646101.1 2013-12-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/030,671 A-371-Of-International US10555962B2 (en) 2013-10-21 2014-10-20 Use of icaritin in preparing medicament for preventing or treating hematocytopenia
US16/724,573 Continuation US10799521B2 (en) 2013-10-21 2019-12-23 Use of icaritin in preparing medicament for preventing or treating hematocytopenia

Publications (2)

Publication Number Publication Date
WO2015058664A1 WO2015058664A1 (zh) 2015-04-30
WO2015058664A8 true WO2015058664A8 (zh) 2016-04-21

Family

ID=52992267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/088944 WO2015058664A1 (zh) 2013-10-21 2014-10-20 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途

Country Status (6)

Country Link
US (2) US10555962B2 (zh)
EP (1) EP3061452B1 (zh)
JP (1) JP6294476B2 (zh)
KR (1) KR101891505B1 (zh)
ES (1) ES2698620T3 (zh)
WO (1) WO2015058664A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276544A (zh) * 2018-11-12 2019-01-29 中国医学科学院药用植物研究所 一种水合淫羊藿素纳米粒及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101891505B1 (ko) * 2013-10-21 2018-08-24 루난 파마슈티컬 그룹 코퍼레이션 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 안히드로이카리틴의 용도
CN110146600B (zh) * 2018-02-13 2022-04-26 国药集团同济堂（贵州）制药有限公司 补骨脂标准汤剂的制备方法及其检测方法
CN111375048A (zh) * 2018-12-27 2020-07-07 北京第一生物化学药业有限公司 脾氨肽在制备治疗白细胞减少症的药物中的应用
CN110156854A (zh) * 2019-05-30 2019-08-23 西安交通大学 一种二氢菲苷类化合物及其提取分离方法和应用
CN113368099B (zh) * 2020-03-10 2024-03-26 鲁南制药集团股份有限公司 淫羊藿苷元在制备血小板功能异常相关疾病防治药物中的用途
CN112369404A (zh) * 2020-10-13 2021-02-19 杭州市第一人民医院 一种肾脏保存液的改良方法
CN114887034B (zh) * 2022-07-14 2022-10-28 中山莱博瑞辰生物医药有限公司 LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途
CN116999391A (zh) * 2023-08-08 2023-11-07 广州沙艾生物科技有限公司 一种car-t细胞制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4696M (zh) * 1965-06-23 1966-12-26
US6399579B1 (en) 2000-08-15 2002-06-04 Hauser, Inc. Compositions comprising icariside I and anhydroicaritin and methods for making the same
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
AU2004242091C1 (en) * 2003-05-07 2009-12-24 La Jolla Institute For Molecular Medicine Administration of hyaluronic acid to enhance the function of transplanted stem cells
CN1194701C (zh) * 2003-06-08 2005-03-30 浙江大学 淫羊藿素或去甲基淫羊藿素在制备雌激素受体调节剂中的应用
CN101607976B (zh) 2008-06-19 2013-09-04 贵州省中国科学院天然产物化学重点实验室 一种淫羊藿苷的制备方法
CN101637467A (zh) 2009-08-18 2010-02-03 贾晓斌 淫羊藿苷元或环淫羊藿苷元磷脂复合物及其制备方法
CN102440986B (zh) 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
US9301942B2 (en) 2013-05-31 2016-04-05 Beijing Shenogen Pharma Group Ltd. Use of icaritin for the preparation of composition for treating cancer
KR101891505B1 (ko) * 2013-10-21 2018-08-24 루난 파마슈티컬 그룹 코퍼레이션 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 안히드로이카리틴의 용도
AU2015209143A1 (en) * 2014-01-23 2016-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276544A (zh) * 2018-11-12 2019-01-29 中国医学科学院药用植物研究所 一种水合淫羊藿素纳米粒及其制备方法和应用

Also Published As

Publication number Publication date
EP3061452B1 (en) 2018-10-03
ES2698620T3 (es) 2019-02-05
EP3061452A1 (en) 2016-08-31
US10799521B2 (en) 2020-10-13
US10555962B2 (en) 2020-02-11
US20200147115A1 (en) 2020-05-14
JP6294476B2 (ja) 2018-03-14
EP3061452A4 (en) 2017-05-03
US20160250243A1 (en) 2016-09-01
KR20160070152A (ko) 2016-06-17
KR101891505B1 (ko) 2018-08-24
WO2015058664A1 (zh) 2015-04-30
JP2016534074A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
WO2015058664A8 (zh) 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途
PH12017502298A1 (en) Antibacterial compounds
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
TW201614068A (en) Fucosidase from bacteroides and methods using the same
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
WO2015073587A3 (en) Synthetic membrane-receiver complexes
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
HK1190738A1 (zh) 具有抑制呼吸道病毒感染的活性的肽及其應用和製備方法
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP2941418A4 (en) N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
WO2015027121A3 (en) Cancer treatment
WO2017079403A3 (en) Polymeric nanoparticles
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
MY175015A (en) A composition for diabetic wound treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14855388

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016525940

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15030671

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014855388

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014855388

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167013370

Country of ref document: KR

Kind code of ref document: A